Debiopharm Group

Raidium is a Medtech company specializing in radiology-augmented technology. It is developing the first radiological foundation model, often referred to as the "GPT-4" of radiology, to simplify precision medicine. Raidium's deep learning algorithms analyze medical imaging data, providing AI-assisted diagnoses to radiologists via an integrated console. This enables earlier detection and management of serious conditions like cancer and cardiovascular diseases.

Tune Insight is a developer of data security software that facilitates secure collaborations on sensitive data among multiple organizations. The company employs advanced collective analytics, privacy measures, and encryption technologies to enable federated learning. This approach allows participants to derive insights collectively while maintaining full control over their own data. By focusing on secure data sharing, Tune Insight empowers organizations to make informed decisions collaboratively, ensuring both data integrity and privacy throughout the process.

WhiteLab Genomics specializes in the development of a proprietary platform that integrates graph knowledge technology and machine learning to advance genomic therapies. The company assists genomic medicine scientists in obtaining accurate and comprehensive insights into essential scientific and technological inquiries. This includes optimizing vector design, assessing genotoxicity, and establishing optimal experimental protocols for both in vivo and in vitro applications. WhiteLab Genomics supports clients throughout the in-silico development phase, facilitating the rapid development of target vectors and payloads, ultimately expediting the delivery of innovative genomic therapies to patients. By processing a wide array of scientific, technical, biological, and genomic datasets, the company enhances the efficiency of research and development in gene and cell therapies.

Novadiscovery SAS, based in Lyon, France, specializes in the development of Jinko, an in silico clinical trial simulation platform. Established in 2010, the company aims to support pharmaceutical and biotech firms in conducting virtual trials, allowing for the prediction of clinical benefits of new drugs prior to human testing. The platform is particularly focused on areas such as immuno-oncology, orphan diseases, metabolic diseases, and cardiotherapy. By leveraging advanced mathematics and intelligent algorithms, Jinko creates a virtual patient community that serves as digital lab rats, enabling researchers to optimize drug development, assess efficacy, and reduce associated costs.

Little Green House operates a chain of educational centers and schools focused on enhancing children's cognitive abilities while fostering emotional well-being and social competence. The centers are designed to create an inclusive environment where children can express themselves freely and explore their potential. Through a variety of developmental activities, including play areas, site visits, and music lessons, Little Green House promotes holistic growth in children, supporting their overall development in a nurturing setting. The company's vision is to empower every child to be their authentic self and to pursue their aspirations.

Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and learning solutions tailored for employees. The company provides an innovative learning experience platform that offers a diverse catalog of training courses in the form of MOOCs. These courses consist of short sessions accessible at any time and on various devices, allowing users to engage with customized content that meets their specific learning needs. Coorpacademy aims to revolutionize digital learning by enhancing accessibility and personalization in employee training.

Immunexpress Pty Ltd is a molecular diagnostics company specializing in the development of clinical assays for the management of immune disorders, particularly focusing on the early detection and management of sepsis. Founded in 2006 and based in Brisbane, Australia, with an additional office in Seattle, the company engages in the discovery and clinical validation of genomic and proteomic biomarkers. These biomarkers are translated into clinical diagnostic and monitoring assays suitable for various platforms, including point-of-care settings. Immunexpress offers several products, such as SeptiCyte Triage, which is designed for use in emergency and intensive care units to differentiate sepsis from other forms of systemic inflammation, as well as SeptiCyte STAT and SeptiCyte RTT, which aid in the monitoring and assessment of immune responses in high-risk patients. The company, previously known as Athlomics Pty Ltd, rebranded to Immunexpress in 2011, reflecting its commitment to advancing sepsis diagnostics.

GenePOC Inc. is a privately owned company that specializes in developing molecular diagnostic solutions to detect pathogen genes efficiently and affordably. As a member of the Debiopharm Group, GenePOC has created a portable and stand-alone device that utilizes unique microfluidic and centripetal technologies. This innovative system aims to enhance the prevention and early detection of infectious diseases, providing healthcare professionals and patients with rapid and cost-effective Point of Care molecular diagnostic tests. Through its focus on simplifying the diagnostic process, GenePOC is committed to improving healthcare outcomes in the field of infectious disease management.

Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and learning solutions tailored for employees. The company provides an innovative learning experience platform that offers a diverse catalog of training courses in the form of MOOCs. These courses consist of short sessions accessible at any time and on various devices, allowing users to engage with customized content that meets their specific learning needs. Coorpacademy aims to revolutionize digital learning by enhancing accessibility and personalization in employee training.

Immunexpress Pty Ltd is a molecular diagnostics company specializing in the development of clinical assays for the management of immune disorders, particularly focusing on the early detection and management of sepsis. Founded in 2006 and based in Brisbane, Australia, with an additional office in Seattle, the company engages in the discovery and clinical validation of genomic and proteomic biomarkers. These biomarkers are translated into clinical diagnostic and monitoring assays suitable for various platforms, including point-of-care settings. Immunexpress offers several products, such as SeptiCyte Triage, which is designed for use in emergency and intensive care units to differentiate sepsis from other forms of systemic inflammation, as well as SeptiCyte STAT and SeptiCyte RTT, which aid in the monitoring and assessment of immune responses in high-risk patients. The company, previously known as Athlomics Pty Ltd, rebranded to Immunexpress in 2011, reflecting its commitment to advancing sepsis diagnostics.

Immunexpress Pty Ltd is a molecular diagnostics company specializing in the development of clinical assays for the management of immune disorders, particularly focusing on the early detection and management of sepsis. Founded in 2006 and based in Brisbane, Australia, with an additional office in Seattle, the company engages in the discovery and clinical validation of genomic and proteomic biomarkers. These biomarkers are translated into clinical diagnostic and monitoring assays suitable for various platforms, including point-of-care settings. Immunexpress offers several products, such as SeptiCyte Triage, which is designed for use in emergency and intensive care units to differentiate sepsis from other forms of systemic inflammation, as well as SeptiCyte STAT and SeptiCyte RTT, which aid in the monitoring and assessment of immune responses in high-risk patients. The company, previously known as Athlomics Pty Ltd, rebranded to Immunexpress in 2011, reflecting its commitment to advancing sepsis diagnostics.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

BPA Solutions SA is a global provider of innovative business applications and solutions that enhance Microsoft SharePoint and Office 365 environments. Founded in 2001 and headquartered in Yverdon-les-Bains, Switzerland, the company develops a suite of regulatory software solutions that focus on quality management, risk management, and compliance with regulations such as GDPR. Their product offerings include BPA CRM, designed for frontline workforce management; BPA Quality for quality assurance; and BPA Risk for tracking business activities in complex environments. Additionally, BPA Solutions provides project management tools, recruitment solutions, and a Self-Service platform for process sharing with external communities. The company also offers a Solution Builder to facilitate the development of integrated components for enhanced user experiences. BPA Solutions serves clients through on-premise, private cloud, or hybrid environments and supports its offerings with professional services like training, installation, and project management. With operations in Switzerland, the United States, and India, BPA Solutions is positioned to support digital workplace initiatives globally.

Skioo is a company dedicated to enhancing the skiing experience by providing a seamless platform for ski ticketing and adventure booking. The Skioo Pass offers skiers instant access to an extensive network of partner resorts in Switzerland and beyond. By integrating with the systems of ski resorts, ski-lift operators, and online accommodation platforms, Skioo simplifies the booking process for users, allowing them to purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community of skiing enthusiasts and provides valuable information and features to enrich the skiing experience. Founded in 2019 as part of Skitude, Skioo is driven by a team of outdoor enthusiasts and collaborates with notable technology partners to deliver its services effectively.

Urturn is the new social platform for self-expression. Both on the Desktop and as an iPhone app, users are able to spontaneously capture moments of inspiration on-the-fly! The ever-growing library of Expression can be instantly personalised in all kinds of ways and the unique 'Your Turn' button lets users take inspiration from or join in with online movements in rich and interactive way. Spontaneous, engaging and fun, Urturn is the next natural step for social media. It's Urturn...

Compliant Concept AG is a Swiss company founded in 2009, specializing in the development of intelligent bed systems aimed at the treatment and prevention of pressure ulcers. Originating from a collaboration between the ETH Zurich and Empa, the company focuses on enhancing patient care in hospitals and nursing homes by providing innovative mobility monitors and risk management solutions. These systems not only assist in clinical risk assessments but also take into account various factors influencing patient care, such as medication and pre-bedtime activities. By automating routine tasks, Compliant Concept aims to reduce the workload for healthcare professionals, thereby improving overall care quality and creating a safer and more comfortable environment for patients.

Spinomix is a Swiss technology platform company based at the Ecole Polytechnique Fédérale de Lausanne (EPFL), specializing in innovative sample processing solutions for the life sciences sector. The company aims to establish a new standard for the processing of biochemical substances, significantly enhancing the quality and efficiency of sample extraction and analysis. Spinomix focuses on critical applications that influence treatment decisions across various human diseases, as well as in animal health and food safety. Its flagship products, MagPhase™ and FibroTrap™, address the challenges posed by complex and heterogeneous samples such as blood, urine, and food matrices, improving both the accuracy and speed of diagnostic results. By leveraging advanced magnetic nanoparticles and microfluidics, Spinomix's automated systems promise to reduce labor intensity and streamline sample processing. The company targets high-growth markets, including nucleic acids extraction and molecular diagnostics, and is actively engaging in collaborations with industry players to validate its technologies and pursue strategic commercial partnerships.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Skioo is a company dedicated to enhancing the skiing experience by providing a seamless platform for ski ticketing and adventure booking. The Skioo Pass offers skiers instant access to an extensive network of partner resorts in Switzerland and beyond. By integrating with the systems of ski resorts, ski-lift operators, and online accommodation platforms, Skioo simplifies the booking process for users, allowing them to purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community of skiing enthusiasts and provides valuable information and features to enrich the skiing experience. Founded in 2019 as part of Skitude, Skioo is driven by a team of outdoor enthusiasts and collaborates with notable technology partners to deliver its services effectively.

Tweasy is a provider of online marketing services that specializes in helping small businesses, clubs, and associations strengthen their customer relationships. The company offers a cloud-based e-Marketing platform designed to facilitate communication by consolidating news, promotions, surveys, and other relevant information. By utilizing local, social, and mobile marketing strategies, Tweasy enables its clients to effectively engage with their customers and foster profitable relationships.

Immunexpress Pty Ltd is a molecular diagnostics company specializing in the development of clinical assays for the management of immune disorders, particularly focusing on the early detection and management of sepsis. Founded in 2006 and based in Brisbane, Australia, with an additional office in Seattle, the company engages in the discovery and clinical validation of genomic and proteomic biomarkers. These biomarkers are translated into clinical diagnostic and monitoring assays suitable for various platforms, including point-of-care settings. Immunexpress offers several products, such as SeptiCyte Triage, which is designed for use in emergency and intensive care units to differentiate sepsis from other forms of systemic inflammation, as well as SeptiCyte STAT and SeptiCyte RTT, which aid in the monitoring and assessment of immune responses in high-risk patients. The company, previously known as Athlomics Pty Ltd, rebranded to Immunexpress in 2011, reflecting its commitment to advancing sepsis diagnostics.

Agendia, Inc., established in 2003 and headquartered in Irvine, California, specializes in developing and distributing genomic-based diagnostic kits for cancer patients. The company's molecular diagnostic technology analyzes the complete human genome to provide physicians with crucial information about a patient's cancer, enabling personalized treatment plans. Agendia's breast cancer tests, for instance, help assess individual risk for metastasis and guide decisions on chemotherapy, hormonal therapy, or alternative treatments, thereby improving patient outcomes and reducing healthcare costs.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Curis, Inc. is a biotechnology company focused on the discovery and development of innovative drug candidates for the treatment of various human cancers. Headquartered in Lexington, Massachusetts, Curis is engaged in advancing its clinical-stage drug candidates, which include CA-4948, an oral small molecule currently in Phase I trials for non-Hodgkin lymphomas and acute myeloid leukemia, as well as monoclonal antibody CI-8993 and the oral dual inhibitor Fimepinostat for specific cancer types. The company's pipeline also features CA-170, aimed at advanced solid tumors and lymphomas, and CA-327, a pre-investigational drug candidate. Curis collaborates with notable organizations such as F. Hoffmann-La Roche and Genentech for the development of Erivedge, a treatment for advanced basal cell carcinoma, and partners with Aurigene Discovery Technologies and DarwinHealth to enhance its capabilities in immuno-oncology and precision oncology. Founded in 2000, Curis is committed to leveraging its expertise in signaling pathways to create targeted therapies for cancer treatment.